Armata Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $169.2M
- Price
- $4.55
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.22%
- Volume
- 22.9K
About
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
Quick stats
Shares outstanding37.2M
Computed float20.3M
Float / shares54.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000921114
Websitehttps://www.armatapharma.com
AI Summary
AI-generated1/9
standardbullishearnings
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
Armata Pharmaceuticals reported Q2 2026 grant revenue of $2.5 million and announced key regulatory milestones for its lead asset AP-SA02, including FDA Fast Track designation and the submission of a Phase 3 protocol targeting initiation in the second half of 2026.
The company recorded a net income of $74.1 million driven by a $91.0 million non-cash gain on its Convertible Loan, though operating losses widened to $10.3 million due to higher R&D and G&A expenses. Armata strengthened its balance sheet with a $25.0 million term loan in May, ending the quarter with $24.0 million in unrestricted cash.
Corporate updates included the promotion of David House to Chief Financial Officer and the appointment of healthcare executive Daniel B. Gilmer to the Board of Directors.
Red flags
- Net income of $74.1M driven by $91M non-cash fair value gain on Convertible Loan, obscuring operating performance
- Operating loss widened to $10.3M from $6.8M YoY
- Unrestricted cash position of $24.0M remains tight relative to burn rate